Robin Dore, MD is a board-certified rheumatologist practicing in Tustin, CA. She is a clinical professor of medicine at UCLA and a member of the Alliance for Patient Access.
Earlier this year the FDA approved a first-of-its-kind drug: a biosimilar. This is an imitation form of a cell-derived, or biologic, medication. Biosimilars could offer